In vivo effects of tumor necrosis factor-α or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 281-287

  D'Alessandro, Natale ^a   Borsellino, Nicole ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

B16 melanoma; Doxorubicin; Flavone acetic acid; Multidrug resistance; Tumor necrosis factor

Indexed keywords

DOXORUBICIN; MITOFLAXONE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; MELANOMA B16; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030013209     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00007     Document Type: Article

References (32)

1. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79: 285-96.
2. Morrow CS, Cowan K. Drug resistance and cancer. In: Yang SS, Warner HR, eds. The underlying molecular, cellular, and immttnological factors in cancer and aging. New York: Plenum Press 1993: 287-305.
3. Sznol M, Long DL. Chemotherapy drug interactions with biological agents. Semin Oncol 1993; 20: 80-93.
4. Borsellino N, Crescimanno M, Flandina C, et al. Antiproliferative and chemomodulatory effects of interferongamma on doxorubicin-sensitive and -resistant tumor cell lines. Anti-Cancer Drugs 1993; 4: 265-272.
5. Scala S, Pacelli R, laffaioli RV, et al. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 1991; 51; 4898-902.
6. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 1992; 52: 6630-37.
7. Cimoli G, Valenti M, Venturini M, et al. Reversion of atMDR by tumor necrosis factor on ovarian cancer cell line. Proc Am Ass Cancer Res 1993; 34; 328.
8. Borsellino N, Crescimanno M, Flandina C, et at. Combined activity of interleukin-lalpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. Anticancer Res 1994; 14: 2643-8.
9. Licht T, Lubbert M, Martens C, et al. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. Cytokines Mol Ther 1995; 1; 123-32.
10. Dwyer PJ, Shoemaker D, Zaharko DS, et al. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent. Cancer Chemother Pharmacol 1987; 19; 6-10.
11. Mace KF, Hornung RL, Wiltrout RH, Young HA. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 1990; 50: 1742-7.
12. Mahadevan V, Malik STA, Meager A, et al. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990; 50: 5537-42.
13. Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor-alfa messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethyIxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994; 54: 870-72.
14. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 269-90.
15. Honma Y, Honma C, Bloch A. Mechanisms of interaction between antineoplastic agents and natural differentiation factors in the induction of leukemic cell differentiation. Cancer Res 1986; 46; 6311-5.
16. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987; 47: 2403-6.
17. Utsugi T, Mattern MR, Mirabelli CK, Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 1990; 50: 2636-40.
18. Kikuchi A, Holan V, Minowada J. Effects of tumor necrosis factor alpha, interferon alfa and interferon gamma on non-Iymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation. Cancer Immunol Immunother 1992; 35: 257-63.
19. Regenass U, Muller M, Curschellas E, Matter A. Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 1987; 39: 266-73.
20. Krosnick JA, Mule' JJ, Mclntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989; 49: 3729-33.
21. Jones AL, Millar JL, Millar BS, et al. Enhanced anti-tumor activity of carmustine (BCNU) with tumor necrosis factor in vitro and in vivo. Br J Cancer 1990; 62: 776-780.
22. Maruo Y, Konno H, Baba S. Therapeutic effects of liposomal adriamycin in combination with tumor necrosis factor-alpha. J Surg Oncol 1992; 49: 20-4.
23. Mihich E, Ehrke MJ. Immunomodulation by anticancer drugs in therapeutics. In: D'Alessandro N, Mihich E, Rausa L, Tapiero H, Tritton TR, eds. Cancer therapy: differentiation, immunomodiilation and angiogenesis. Berlin: Springer Verlag 1993: 121-33.
24. Jones AL, O'Brien MER, Lorentzos A, et al. A randomised phase II study of carmustine alone or in combination with tumor necrosis factor in patients with advanced melanoma. Cancer Cbemother Pbarmacol 1992; 30: 73-76.
25. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
26. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha tumor necrosis factor, gamma-interferon and melphalan. Cancer 1994; 73: 483-92.
27. Winkelhake JL, Stampfl S, Zimmerman RJ. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 1987; 47; 3948-53.
28. Formelli F, Supino R, Cleris L, Mariani M. Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo. Br J Cancer 1988; 57: 343-7.
29. Amikura K, Veo KT, Dvorak HF, et al. Expression of vascular endothelial growth factor correlates with tumor necrosis factor cytotoxicity in vivo. Proc Am Ass Cancer Res 1995; 36: 468.
30. Ferraiolo BL, Moore JA, Grase D, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis-alpha in mice. Drug Metab Disp 1988; 16: 270-5.
31. Debs RJ, Fuchs HG, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990; 50: 375-80.
32. Damia G, Zanette ML, Rossi C, et al. Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemother Pharmacol 1988; 22: 47-50.